TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06732492

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is comparing RD13-02 cell infusion against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 3 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

RD13-02 cell infusion (DRUG): CAR-T cells

Drugs / treatments
RD13-02 cell infusion
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

NCT06732492

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is comparing RD13-02 cell infusion against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 3 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

RD13-02 cell infusion (DRUG): CAR-T cells

Drugs / treatments: RD13-02 cell infusion

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 10 patients

Primary endpoint: Overall response rate (ORR)

Ages: 3 Years to 70 Years

Start date: 2024-10-31 | Est. completion: 2027-12-31

Locations

0 US sites · 1 total

Contact

Heng Mei, Ph.D&M.D | hmei@hust.edu.cn | 027-8572600

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06732492

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.